Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer (ADAPT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01815242
Recruitment Status : Active, not recruiting
First Posted : March 21, 2013
Last Update Posted : July 23, 2019
Sponsor:
Collaborator:
Celgene
Information provided by (Responsible Party):
West German Study Group